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Abstract
Glycogen phosporylase (GP) is a promising target for the control of glycaemia. The design of inhibitors binding at the catalytic site
has been accomplished through various families of glucose-based derivatives such as oxadiazoles. Further elaboration of the
oxadiazole aromatic aglycon moiety is now reported with 3-glucosyl-5-amino-1,2,4-oxadiazoles synthesized by condensation of a
C-glucosyl amidoxime with N,N’-dialkylcarbodiimides or Vilsmeier salts. The 5-amino group introduced on the oxadiazole scaf-
fold was expected to provide better inhibition of GP through potential additional interactions with the enzyme’s catalytic site;
however, no inhibition was observed at 625 µM.
Introduction
Glycogen phosphorylase (GP) is a homodimeric enzyme that is
responsible for the depolymerization of glycogen into glucose-
1-phosphate, which is further converted into glucose delivered
into the blood stream [1,2]. The control of GP activity could
find application in the treatment of hyperglycemia for type 2
diabetes patients [3-7]. Seven binding sites have been identified
for GP and the design of various classes of inhibitors has
attracted much attention [8-12]. C-Glycosylated heterocycles
have been designed and synthesized and displayed low micro-
molar to even sub-micromolar Ki values against GP (Figure 1)
[9-13]. Benzo-fused aglycons [14,15] (A–C) were initially iden-
tified as beneficial for the inhibition of GP. 1,2,3-Triazolyl-
based aglycon D [16,17] proved valuable for the inhibition of
GP and further design around the triazole moiety was also
reported [18,19]. The isomeric 1,2,4-triazole E was recently
identified as a sub-micromolar GP inhibitor [20,21] and high-
lights the influence of the aromatic moiety used in these studies.
The influence of the heterocyclic moiety was also clearly
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Figure 1: Structures of the glycosylated heterocyclic GP inhibitors and corresponding Ki values against RMGPb.
demonstrated in a structure–activity relationship study with
several isomeric oxadiazoles. The regioisomeric substitution
around the 1,2,4-oxadiazoles (F [22,23] vs G [23,24]) plays a
role in the inhibition observed with the glucosyl group at the
5-position of the 1,2,4-oxadiazole ring being preferred. Isomeric
1,3,4-oxadiazole H [25] was practically inactive against GP in
comparison to its 1,2,4-oxadiazole congeners (F and G). Never-
theless, inhibition could be restored by introducing a nitrogen
atom (NH) between the glucosyl and aromatic aglycon (I [26]),
while introduction on the other position (J [27]) did not help.
The structure–activity relationship of 5-aryl-1,2,4-oxadiazoles F
and G towards GP inhibition highlighted a set of interactions of
the aryl moieties with the enzyme’s β-channel [22-24]. The
amino acids present in this empty pocket are of mixed char-
acter and can accommodate hydrophobic groups such as aryl
moieties, with 2-naphthyl identified as the best pharmacophore
for the series discussed above (Figure 1, D–I). Nevertheless,
hydrogen bonds might also be created in this secondary binding
site with other residues. The introduction of hydrogen bond
donors and/or acceptors at the 5-position of the oxadiazole
could provide better ligands for this enzyme through additional
interactions with the β-channel amino acid residues (Figure 2).
Nevertheless, introduction of a tetrahedral atom in the aglycon
usually weakens the inhibitory properties [8-12]. The introduc-
tion of an amino functionality between the 1,3,4-oxadiazole
core and glucose [26] (I) or aromatic [27] (J) groups was
recently investigated (Figure 1). The present study reports on
the introduction of such amino groups between the oxadiazole
and aromatic cores. Two synthetic strategies were used to
obtain such scaffolds based on recent and unprecedented litera-
ture reports.
Results and Discussion
Synthesis of 3-glucosylated 5-amino-1,2,4-
oxadiazoles
The target GP inhibitor scaffold was obtained from the conden-
sation of Vilsmeier salts with the C-glucosyl-amidoxime 3 [28]
in the presence of a base. This condensation was very recently
reported in the context of heterocyclic chemistry [29] and we
have applied it with success to our GP inhibitor design. The di-
methylamino group (Scheme 1, a) was chosen as a small phar-
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Figure 2: Structures of the two targeted 3-glucosyl-5-amino-1,2,4-oxadiazoles.
macophore that can be readily accommodated in the GP’s
catalytic site. Aromatic moieties were also selected (Scheme 1,
b and c) for their expected hydrophobic contact with the
enzyme. The tetrahydroisoquinoline moiety (Scheme 1, c) was
particularly interesting due to its structural analogy with the
2-naphthyl residue, which is identified as the best pharma-
cophore in the GP inhibitor series. The morpholinyl (Scheme 1,
d) and piperidinyl (Scheme 1, e) residues were also selected as
candidates for their hydrophobic properties, although they are
bulkier than aromatic rings.
The synthesis started with commercially available ureas (2a and
2e) or through the synthesis of such ureas. While the synthesis
from carbonyl diimidazole was not successful [30], and since
phosgene was not considered due to its hazardous reaction
conditions, ureas 2b–d could be readily prepared from triphos-
gene 1 (as a phosgene precursor) and the corresponding amines
(Scheme 1). While treatment of triphosgene with the corre-
sponding amine at room temperature in dichloromethane [31]
was sufficient for ureas 2a,c–e, heating (40 °C) and the add-
ition of triethylamine [32] were required for condensation with
N-methylbenzylamine to obtain urea 2b. The Vilsmeier salt was
then generated in situ with oxalyl chloride from the corre-
sponding ureas and condensation with C-glucosyl-amidoxime 3
afforded the desired 3-glucosylated 5-amino-1,2,4-oxadiazoles
4a–e in moderate yields. Even though these results are modest,
they are in agreement with the yields reported in the literature
[29] for such condensations. Removal of the benzoate esters
provided the desired GP inhibitor candidates 5a–e.
The syntheses of 3-glucosyl-5-alkylamino-1,2,4-oxadiazoles
7a,b were readily achieved by condensation of the C-glucosyl
amidoxime 3 [28] with N,N’-dialkylcarbodiimides under
refluxing toluene (Scheme 1) [33-35]. To this end, conden-
sation of amidoxime 3 [28] with commercially available
carbodiimides (R = iPr, C6H11, tolyl) provided the desired
5-alkylaminooxadiazoles 6a,b in quantitative yields and depro-
tection of the glucopyranose ring under Zemplén conditions
afforded the O-unprotected GP inhibitor candidates 7a,b. No
reaction was observed with the N,N’-ditolylcarbodiimide,
Scheme 1: Synthesis of 3-glucosyl-5-amino-1,2,4-oxadiazoles.
although the starting material was consumed. The mechanism
proposed by Ispikoudi et al. [33] proposes the amine moiety as
a leaving group during this process. Anilines (R = tolyl) are
worse leaving groups than alkylamines (R = iPr, C6H11), thus
providing a likely explanation regarding the non-reactivity
observed for this substrate.
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Enzymatic inhibition studies (RMGPb)
The seven 3-glucosyl-5-amino-1,2,4-oxadiazoles 5a–e and 7a,b
were evaluated as GP inhibitors using rabbit muscle glycogen
phosphorylase b (RMGPb) as the model enzyme (see
Supporting Information File 1 for details). The highest concen-
tration used in the assay was 625 µM for compatibility of the
DMSO stock solutions with the enzymatic reaction. No inhibi-
tion could be observed at this concentration.
This result compares unfavorably to the C-glucosylated hetero-
cyclic inhibitors A–F (IC50 ~µM) [22,23]. These poor
inhibitory properties could be due to limited interactions of
alkyl groups in the β-channel of GP in comparison to aromatic
moieties. This lack of GP inhibition for a 5-aminooxadiazole
can be correlated with the lack of inhibition of compound J in
the 1,3,4-oxadiazole series (Figure 1). While the introduction of
an NH moiety between the anomeric carbon atom and the
heteroaryl group was actually beneficial (compare H to I in
Figure 1), the same NH moiety at the 5-position of the 1,3,4-
oxadiazole ring was highly detrimental (compare I to J in
Figure 1).
Conclusion
In conclusion, we have synthesized seven 3-glucosyl-5-amino-
1,2,4-oxadiazoles by condensation of a C-glucosyl amidoxime
with Vilsmeier salts or carbodiimides. The synthetic strategy
provided access to 5-alkylamino and 5-dialkylamino-1,2,4-
oxadiazoles from the same glucose-based amidoxime precursor.
Symmetric ureas were synthesized and converted into their
Vilsmeier salts, which upon condensation with the amidoxime
afforded the dialkylated 5-amino-1,2,4-oxadiazoles. Conden-
sation of three commercially available carbodiimides led to two
mono-alkylated 5-amino products, while the aromatic (i.e.,
tolyl) carbodiimide did not provide the desired product. A series
of seven glucose-based inhibitors of GP were then evaluated but
did not display any inhibition against RMGPb at 625 µM.
Supporting Information
Supporting Information File 1
Experimental details and NMR data for all new compounds
as well as enzyme kinetics (IC50) measurements.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-11-56-S1.pdf]
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